Skip to content
Screener

Abbott ABT Total Revenue

Total Revenue at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$4.98B-9.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$592.1M+1.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$25.31B+6.6%
Haemonetics logo
HaemoneticsHAE
$339.38M+5.6%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$381.88M+7.5%
Boston Scientific logo
Boston ScientificBSX
$5.44B+7.5%

Segments

By geography

See full
United States$5.22B
Germany$2.35B+0.2%
China$2.25B+5.6%
India$1.75B+6.1%
Switzerland$1.64B+22.6%
Japan$1.51B-21.7%

By segment

See full
Medical Devices$5.85B+9.0%
Diagnostic Products$3.09B+42.3%
Nutritional Products$2.14B-3.1%
Established Pharmaceuticals$1.5B+8.4%

Other financials

Income statement

See full
Gross profit$7.3B+15.6%
Operating income$1.7B-17.5%
Net income$928.0M-47.8%
EPS (diluted)$0.53-47.5%

Balance sheet

See full
Cash & equivalents$5.1B-26.6%
Total debt$32.6B+143%
Total equity$51.1B+1.1%
Total assets$109.22B+30.0%

Cash flow

See full
Operating cash flow$2.5B+21.5%
CapEx$497.0M-1.0%
Free cash flow$2.0B+28.9%

Valuation

See full
Market cap$197.44B-13.7%
Enterprise value$224.94B-4.4%
P/E36.4×+20.0×
P/S4.2×-1.1×

Profitability

See full
Gross margin56.6%+0.6pp
Operating margin15.8%-1.7pp
Net margin11.6%-20.8pp
FCF margin16.8%+1.1pp

Returns & leverage

See full
Return on equity10.7%-20.4pp
Debt / equity0.6×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Abbott’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050134
Line itemThree Months Ended / June 30 / 2026Three Months Ended / June 30 / 2025Six Months Ended / June 30 / 2026Six Months Ended / June 30 / 2025
Net sales$12,593$11,142$23,757$21,500
Cost of products sold, excluding amortization of intangible assets5,3254,85410,2159,322
Amortization of intangible assets6584201,080840
Research and development8927251,6591,441
Selling, general, and administrative4,0253,0917,7656,152
Total operating cost and expenses10,9009,09020,71917,755
Operating earnings1,6932,0523,0383,745
Interest expense351121525252

Item 1. Financial Statements and Supplementary Data

FAQ

What is Abbott's total revenue?
Abbott (ABT) reported total revenue of $12.59B in Q2 2026.
How has Abbott's total revenue changed year-over-year?
Abbott's total revenue increased by 13.0% year-over-year, from $11.14B to $12.59B.
What is the long-term trend for Abbott's total revenue?
Over 4 years (2021 to 2025), Abbott's total revenue has grown at a 0.7% compound annual growth rate (CAGR), from $43.08B to $44.33B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Abbott's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude